These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 20384388

  • 21. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L, Kunz M, Marr J.
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C, Schellschmidt I, Heithecker R.
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [Abstract] [Full Text] [Related]

  • 23. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L, Buhling KJ, Rybowski S, Roth K, Rosen K.
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [Abstract] [Full Text] [Related]

  • 24. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
    Masson S, Franssen E, Hilditch JR, Powell MG.
    Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
    [Abstract] [Full Text] [Related]

  • 25. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
    Lete I, Chabbert-Buffet N, Jamin C, Lello S, Lobo P, Nappi RE, Pintiaux A.
    Eur J Contracept Reprod Health Care; 2015 Jan; 20(5):329-43. PubMed ID: 26007631
    [Abstract] [Full Text] [Related]

  • 26. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J, Möhner S, Heinemann K.
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [Abstract] [Full Text] [Related]

  • 27. Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women.
    Tantbirojn P, Taneepanichskul S.
    Contraception; 2002 Dec; 66(6):401-5. PubMed ID: 12499031
    [Abstract] [Full Text] [Related]

  • 28. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, Coelingh Bennink HJ.
    Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
    [Abstract] [Full Text] [Related]

  • 29. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH, Gollnick H, Schellschmidt I.
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [Abstract] [Full Text] [Related]

  • 30. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
    Winkler UH, Ferguson H, Mulders JA.
    Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
    [Abstract] [Full Text] [Related]

  • 31. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
    Anttila L, Neunteufel W, Petraglia F, Marr J, Kunz M.
    Clin Drug Investig; 2011 Jun; 31(8):519-525. PubMed ID: 21721590
    [Abstract] [Full Text] [Related]

  • 32. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO, Endrikat J, Düsterberg B, Schmidt W, Gerlinger C, Wessel J, Goldstein H, Jespersen J.
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [Abstract] [Full Text] [Related]

  • 33. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.
    Junge W, Mellinger U, Parke S, Serrani M.
    Clin Drug Investig; 2011 Feb; 31(8):573-584. PubMed ID: 21721593
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [Abstract] [Full Text] [Related]

  • 35. Drospirenone and levonorgestrel in combination with either 30 or 20 mcg ethinylestradiol reduce soluble adhesion molecules in Brazilian women; cross-sectional study.
    Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, Toloi MR.
    Contraception; 2012 Nov; 86(5):506-10. PubMed ID: 22554799
    [Abstract] [Full Text] [Related]

  • 36. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 37. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
    Heger-Mahn D, Pabst G, Dienel A, Schläfke S, Klipping C.
    Drugs R D; 2014 Dec; 14(4):265-72. PubMed ID: 25319228
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebo-controlled trial.
    Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME.
    J Am Acad Dermatol; 2002 Sep; 47(3):399-409. PubMed ID: 12196750
    [Abstract] [Full Text] [Related]

  • 39. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?
    Bird ST, Delaney JA, Etminan M, Brophy JM, Hartzema AG.
    J Thromb Haemost; 2013 Jun; 11(6):1059-68. PubMed ID: 23574590
    [Abstract] [Full Text] [Related]

  • 40. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris.
    Palli MB, Reyes-Habito CM, Lima XT, Kimball AB.
    J Drugs Dermatol; 2013 Jun 01; 12(6):633-7. PubMed ID: 23839178
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.